Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intarcia Therapeutics
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women age 18 to 80 years with type 2 diabetes
On stable treatment regimen of diet and exercise alone or in combination with a stable \& optimal or near-optimal dose of metformin, sulfonylurea, TZD or combination of these drugs
HbA1c \>10.0% and ≤12.0%
You may not be if
Prior treatment with any GLP-1 receptor agonist
History of hypersensitivity to exenatide or liraglutide
FPG \>300 mg/dL
History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2
Taking DPP-4 inhibitors, incretin mimetics, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
history of pancreatitis
Clareo Health | A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
